載入...

Dose-effect relationship for several coagulation markers during administration of the direct thrombin inhibitor S 18326 in healthy subjects

AIMS: We conducted a phase I placebo-controlled trial with two i.v. doses (0.5 mg h−1 and 3 mg h−1) of S 18326, a selective thrombin inhibitor that interacts with the catalytic site of thrombin, with the aim to study the relationships between increasing plasma levels of S 18326 and changes in coagul...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Gaussem, P, Dubar, M, le Bonniec, B, Richard-Lordereau, I, Jochemsen, R, Aiach, M
格式: Artigo
語言:Inglês
出版: Blackwell Science, Ltd 2002
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC1874285/
https://ncbi.nlm.nih.gov/pubmed/11851638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1046/j.0306-5251.2001.01534.x
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!